合伙人信息显示，该基金由中汇人寿保险股份有限公司、上海复星医药产业发展有限公司、弘毅私募基金管理（天津）合伙企业（有限合伙）共同出资。 投时关键词：复星医药（600196.SH） | | 自公司 都在用的商业直向工具 | 查关系 普风险 普敦版 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 中汇复弘(天津)股权投资基金合伙企业(有限合伙) | 0 天蝎一下 部应用 ▼ 企业级产品。 | | 商务合作 | 由 开通会员 · | 鱼 费米· | | 基本信息 3 | 法律诉讼 | 经营风险 | 经营信息 公司发展 | | 知识产权 | 历史信息 ◎ | | | 工商信息 @ | | | | | | | で天眼直 | | 历史工商信息0 工商信息 | | | | | | | 대 특별 | | 企业名称 | 中汇复弘(天津)股权投资基金合伙企业(有限合伙) | | | | | | | | 执行事务合伙人 3 | 弘毅私募基金管理(天津)合伙 企业(有限合伙) (含新代表) Di 围逸清) 委派代表:曹永刚(宋源于中墓 | 登记状 ...

Core Viewpoint - The establishment of the Zhonghui Fuhong Equity Investment Fund in Tianjin marks a new experiment in the integration of finance and industry within the healthcare sector, aiming to unlock new investment paradigms through collaboration among insurance capital, industrial capital, and professional fund management [2][3][4] Group 1: Fund Establishment and Structure - The Zhonghui Fuhong Equity Investment Fund has a total capital of 547 million RMB and is a partnership involving Zhonghui Life Insurance, Fosun Pharma, and Hongyi Private Equity [2] - The fund's operational scope includes private equity investment, investment management, and asset management, indicating a focus on healthcare investments [2] Group 2: Strategic Implications for Participants - The collaboration between insurance capital, industrial capital, and general partners (GPs) is expected to reshape the underlying logic of healthcare investments, with insurance capital seeking stable returns and industrial capital aiming for asset-light transformation [2][3] - Fosun Pharma's strategy involves divesting non-core assets to recover cash flow, which will then be reinvested into high-margin sectors like innovative drugs and CXO services through the fund [3] Group 3: Regional Advantages and Policy Support - Tianjin's status as a free trade zone provides significant policy advantages, such as tax refunds for individual limited partners and facilitation of cross-border capital flows, which lower operational costs for the fund [3][4] - The biopharmaceutical industry park in Tianjin aligns well with Fosun Pharma's strategic layout, enhancing the region's attractiveness for capital investment [3] Group 4: Future Outlook and Potential Impact - The success of the Zhonghui Fuhong Fund could set a precedent for other insurance companies and may lead to a shift in the investment landscape, potentially breaking the dominance of Beijing and Shanghai in healthcare equity investments [3][4] - The efficiency of project exits and the outcomes of industrial collaboration over the next year will determine whether this initiative can evolve from a case study to a replicable model [4]

1月14日金融一线消息，天眼查显示，近日，中汇复弘（天津）股权投资基金合伙企业（有限合伙）成 立，出资额5.47亿元，经营范围为以私募基金从事股权投资、投资管理、资产管理等活动。合伙人信息 显示，该合伙企业由中汇人寿保险股份有限公司、复星医药全资子公司上海复星医药产业发展有限公 司、弘毅私募基金管理（天津）合伙企业（有限合伙）共同出资。 | 工商信息 ● | | | | | | 医 胶摇纠错 | 已天眼色 | | --- | --- | --- | --- | --- | --- | --- | --- | | 工商售應 历史工商信息( | | | | | | | 0 12 6 9 | | 企业名称 | 中汇直弘(天津)股权投资基金台伙企业(有限合伙) | | | | | | | | | 弘扬松基基金管理 (大量)合伙 到日状态(1) 企业(有限合伙) (面试代表: | 存状 | | | | | | | 执行覆务台伙人(3 | 3 厥逸涛) 的单点点 受期代表:疆水刚(火漏子中赞 | 天景评分 8 | | | | 96 | | | | 成立日期 801 | 2026-01-08 | | | | | | | 均 ...

Group 1 - The core point of the article is the establishment of Zhonghui Fuhong (Tianjin) Equity Investment Fund Partnership (Limited Partnership) with a capital contribution of 547 million yuan, focusing on private equity investment, investment management, and asset management activities [1] - The partnership is jointly funded by Zhonghui Life Insurance Co., Ltd., a wholly-owned subsidiary of Fosun Pharma (600196) Shanghai Fosun Pharma Industry Development Co., Ltd., and Hongyi Private Equity Fund Management (Tianjin) Partnership (Limited Partnership) [1] - The establishment of this fund indicates a strategic move in the private equity investment sector, highlighting the collaboration between insurance and pharmaceutical companies [1]

| 序号 | | 合伙人名称 出资比例; 认缴出资额 | | --- | --- | --- | | | 毒 | 中汇人寿保险股份有限公司 器 | | | 保险 | | | | | 上海复星医药产业发展有限公司 品 | | | | 弘毅私募基金管理（天津）合伙企业（有限合伙） 届 | | 2 | | | | 3 | C | | | | | 私募基金管理人 | | | 5- 第七 期一直 | | | | | 国有控股 | | | 皇公司 都在用的商业查询工具 | 童老板 商关系 音风险 | | | | --- | --- | --- | --- | --- | | | 家中小企业发展子其全旗下机构 | 中汇复弘(天津)股权投资基金合伙企业(有限合伙) 8 | 天眼一下 ■ 应用 ▼ | 商务合作 | | 基本信息 3 | 法律诉讼 | 经营风险 | 经营信息 公司发展 | 知i | | 工商信息 ● | | | | | | 工商信息 历史工商信息0 | | | | | | 企业名称 | 中汇复弘（天津）股权投资基金合伙企业（有限合伙） | | | | | 执行事务合伙人 2 | 弘毅私募基金管理(天津) 合伙 ...

天眼查工商信息显示，近日，中汇复弘（天津）股权投资基金合伙企业（有限合伙）成立，执行事务合 伙人为弘毅私募基金管理（天津）合伙企业（有限合伙），出资额5.47亿人民币，经营范围为以私募基 金从事股权投资、投资管理、资产管理等活动。合伙人信息显示，该基金由中汇人寿保险股份有限公 司、上海复星医药产业发展有限公司、弘毅私募基金管理（天津）合伙企业（有限合伙）共同出资。 ...

Core Viewpoint - The report highlights the growth trends in China's chemical pharmaceutical raw materials industry, indicating a steady increase in production and market dynamics from 2025 to 2032 [1] Industry Summary - In November 2025, China's chemical pharmaceutical raw material production reached 331,000 tons, reflecting a year-on-year growth of 1.5% [1] - From January to November 2025, the cumulative production of chemical pharmaceutical raw materials in China was 3,358,000 tons, with a cumulative growth of 1.8% [1] - The report by Zhiyan Consulting provides insights into the supply and demand dynamics of the chemical pharmaceutical industry in China, projecting future trends from 2026 to 2032 [1] Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1]

Group 1 - The core viewpoint of the news highlights a strong performance in innovative drug concept stocks, with notable increases in companies such as WuXi AppTec and Kanglong Chemical, which rose over 7%, and others like Xinlitai, which increased over 3% [1] - The innovative drug-related ETFs also saw significant gains, with an overall increase of over 2% [1] Group 2 - Specific ETF performance includes the Innovative Drug Industry ETF rising by 2.59% to 0.633, and other ETFs like the Innovative Drug ETF and the EasyGo Innovative Drug ETF also showing increases of 2.45% and 2.40% respectively [2] - Analysts indicate that core assets in innovative drugs are expected to continue rising, with new opportunities emerging in areas such as small nucleic acids and in vivo CAR technologies [2] - The long-term trend of innovative drug business development (BD) is seen as a pathway for China's innovative drug capabilities to gain recognition on the global stage, with core assets licensed to multinational corporations (MNCs) expected to realize value as clinical progress continues [2]

Group 1 - The core viewpoint of the news is the recognition of 31 headquarters enterprises in Sichuan Province for 2025, with 22 of them located in Chengdu, highlighting the city's dominance in this area [1][2] - Chengdu has a significant representation in the headquarters enterprise list, with 89 out of 128 recognized enterprises since the initiation of the program in 2024, accounting for nearly 70% [1][2] - The recognized headquarters enterprises are categorized into three types: 12 comprehensive headquarters, 5 functional headquarters, and 5 growth-oriented headquarters, indicating a diverse range of enterprise capabilities [2] Group 2 - The recognition of headquarters enterprises reflects the comprehensive development of the region's industry, with companies like Sichuan Baili Tianheng Pharmaceutical Co., Ltd. achieving a market value exceeding 100 billion yuan, contributing to the local biopharmaceutical sector [3] - Chengdu's favorable business environment is a key factor in attracting headquarters enterprises, as evidenced by its recognition as an "Innovative City of the Year" in the 2024-2025 Urban Business Environment Innovation Report [4] - The "Jin Jie You Cu" initiative, aimed at improving the business environment, has led to significant engagement with local enterprises, resolving over 42,400 issues and enhancing the overall economic landscape [5] Group 3 - The influx of headquarters enterprises is expected to lead to a more complete industrial chain and higher industrial capabilities in Chengdu, enhancing the city's economic structure [6] - Notable headquarters such as Fosun Pharma's nuclear medicine headquarters and other significant projects are set to establish a stronger industrial ecosystem in Chengdu, particularly in the biopharmaceutical and integrated circuit sectors [7][8] - The arrival of these enterprises signifies a new stage of industrial attractiveness for Chengdu, promoting economic growth and the development of a modern industrial system [8]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanguo, has submitted a drug registration application for a new drug targeting ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients, which has been accepted by the National Medical Products Administration [1] Group 1 - The new drug is an innovative small molecule chemical drug [1] - The application is specifically for the treatment of patients with ALK-positive locally advanced or metastatic NSCLC [1] - Another indication for the drug, targeting ROS1-positive non-small cell lung cancer, has completed Phase II clinical trials in mainland China [1]